STORY SUMMARY
FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality
The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.
This is a brief summary of reporting from FDA Press Releases. Read the original for the full article and context.